Apotex Q1 FY27 adjusted EBITDA drops 54% to CAD 259.3 million; revenue falls 25.8% to CAD 848 million

• Apotex posted Q1 FY2027 revenue of CAD 848 million, down 26% year over year; IFRS net loss was CAD 38.3 million.
• IFRS operating income fell 85.29% to CAD 71.7 million, while adjusted EBITDA (non-IFRS) dropped 54.3% to CAD 259.3 million.
• Adjusted EBITDA margin (non-IFRS) narrowed 19 percentage points to 30.6%.
• Canada revenue climbed 11.5% to CAD 412.7 million, while U.S. revenue sank 48.5% to CAD 362.9 million.
• Outlook held for upper mid-single digit revenue growth with ~30% adjusted EBITDA margin; CAD 0.06 dividend declared, payable Sept. 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apotex Health Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: TO24325) on August 12, 2026, and is solely responsible for the information contained therein.